Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update

Blood

Volumn 111, Issue 1, 2008, Pages 25-41

  Rizzo, J Douglas ^a   Somerfield, Mark R ^b   Hagerty, Karen L ^b   Seidenfeld, Jerome ^c   Bohlius, Julia ^d   Bennett, Charles L ^e   Cella, David F ^f   Djulbegovic, Benjamin ^g   Goode, Matthew J ^h   Jakubowski, Ann A ⁱ   Rarick, Mark U ^j   Regan, David H ^k   Lichtin, Alan E ^l   Schwartz, Carol ^m  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c BlueCross BlueShield Association   (United States)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e NORTHWESTERN UNIVERSITY   (United States)

^f EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h Patient Representative   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j KAISER PERMANENTE   (United States)

^k Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m American Society of Hematology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DOXORUBICIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON DEXTRAN; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ANEMIA; ANGINA PECTORIS; BLOOD TRANSFUSION; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; IRON INTAKE; IRON STORAGE; LUNG EMBOLISM; MULTIPLE MYELOMA; MYELODYSPLASIA; MYELOMA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

EID: 38049174952     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-109488     Document Type: Review

References (39)

1. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
2. Food and Drug Adminstration. Oncologic Drugs Advisory Committee briefing document. Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. 2004. http://www.fda.gov/ohrms/dockets/ac/ 04/briefing/4037b2_04.pdf. Accessed October 6, 2007.
3. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer [review]. Cochrane Database Syst Rev. 2007;2:CD003407.
4. Seidenfeld J, Piper M, Bohlius J, et al. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026.) Washington, DC: Agency for Healthcare Research and Quality; 2006. http://www.effectivehealthcare.ahrq.gov/reports/ final.cfm. Accessed October 2, 2007.
5. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-220.
6. Quirt I, Bramwell V, Charette M, et al. The Role of Erythropoietin in the Management of Cancer Patients with Non-hematologic Malignancies Receiving Chemotherapy. Toronto, Ontario: Cancer Care Ontario; 2007. http://www. cancercare.on.ca/pdf/pebc12-1f.pdf. Accessed October 2, 2007.
7. Shehata N, Walker I, Meyer R, et al. Treatment for Anemia with Erythropoietic Agents in Patients with non-Myeloid Hematological Malignancies: A Clinical Practicie Guideline. Toronto, Ontario: Cancer Care Ontario; 2007. http://www.cancercare.on.ca/pdf/pebc6-12s.pdf. Accessed October 6, 2007.
8. Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther. 2006;28:801-831.
9. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
10. Crawford J, Robert F, Perry MC, et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007;2:210-220.
11. Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006;107:1909-1917.
12. Rearden TP, Charu V, Saidman B, et al. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). J Clin Oncol 2004;22:745s. Abstract 8064.
13. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006:106:223-233.
14. Browman GP: Standards of proof, standards of practice, and proof of standards: A tale of two trials. J Clin Oncol. 2005;23:2583-2585.
15. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23:2946-2954.
16. Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol. 2004;15:979-986.
17. Mallinson T, Cella D, Cashy J, et al. Giving meaning to measure: Linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage. 2006;31:229-241.
18. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558-2560.
19. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998;15:174-182.
20. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999;80:396-402.
21. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
22. Food and Drug Administration Oncologic Drugs Advisory Committee Briefing Document. Continuing Reassessment of the Risks of Erythropoiesis-Simulating Agents (ESAs) Administered for the Treatment of Anemia associated with Cancer Chemotherapy. Washington, DC: US Food and Drug Administration; 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf. Accessed October 2, 2007.
23. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol. 1998;103:1070-1074.
24. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960-5972.
25. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
26. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with diseaserelated anemia. J Clin Oncol 2007;25:1027-1032.
27. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007;356:2445-2448.
28. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301-1307.
29. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231-242.
30. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia. 2007;21:627-632.
31. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood. 2004;104:321-327.
32. Abels RI, Larholt KM, Krantz KD, et al. Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer. Oncologist. 1996;1:140-150.
33. Charu V, Belani CP, Gill AN, et al. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: A controlled, randomized, open-label phase II trial. Oncologist. 2007;12:727-737.
34. Gordon DH, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and/or radiotherapy. Blood. 2006;108:328a. Abstract 1304.
35. Mystakidou K, Kalaidopoulou O, Katsouda E, et al. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res. 2005;25:3495-3500.
36. Smith RE Jr, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 2003;88:1851-1858.
37. Danish Head and Neck Cancer Group (DAHANCA). Study of the importance of Novel Erthropoiesis Stimulating Protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carinoma of the head and neck. Aarhus, Denmark: Aarhus University Hospital; 2006. http://www.dahanca.dk/get_media_file. php?mediaid=125. Accessed October 2, 2007.
38. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394-403.
39. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714.